PT-141, sildenafil or tadalafil?
Start with what has changed. Less interest in sex and difficulty getting or keeping an erection can overlap, but they call for different questions. Here is how the treatment approaches compare.
The short answer
Sildenafil and tadalafil help erections in response to sexual stimulation. Bremelanotide, also called PT-141, acts on melanocortin pathways; its strongest desire-treatment evidence comes from trials in premenopausal women with HSDD. A different mechanism does not make it a stronger ED medicine or establish the same benefit for everyone.
Side by side
| PT-141 offered here | Sildenafil / Tadalafil | |
|---|---|---|
| Treatment approach | Central melanocortin signaling | Support for the blood-flow response to sexual stimulation |
| Evidence to understand | Strongest desire evidence: injected bremelanotide studied in premenopausal women with HSDD. Results do not establish equivalence for our compounded product. | Established prescription treatments for erectile dysfunction |
| Form offered | Compounded injection | Oral tablets |
| Schedule | Set by the prescribing clinician | As needed, or daily with tadalafil |
| Regulatory status | Compounded to your prescription; not an FDA-approved drug product | FDA-approved generic tablets |
| Price | From $129/mo | See the treatment pages for current plans |
Is PT-141 better than Viagra?
There is no basis here to rank PT-141 above Viagra for ED. Sildenafil and tadalafil are approved ED treatments. The compounded PT-141 injection is a different preparation with a different evidence base. Describe the change you want addressed, including whether desire, erections or both are involved, rather than choosing from a ranking.
Read: Sildenafil prescribing information; Tadalafil prescribing information.
What does the research say about desire?
The phase 3 bremelanotide studies found improved desire scores and reduced related distress compared with placebo in the studied women. Early studies in men examined erectile responses, not a broadly established treatment for male low libido. Population, route and formulation all matter when interpreting these findings.
Read: Kingsberg et al. Two randomized phase 3 bremelanotide trials; Rosen et al. Subcutaneous PT-141 in healthy men and men with ED.
Safety is part of the comparison
Sildenafil and tadalafil must not be taken with nitrates, including recreational nitrites called poppers, because blood pressure can drop dangerously. Both also have other contraindications and interactions. Review your full medication and substance use with the clinician before treatment.
PT-141 has a separate risk profile, described in our safety guide below. Combining treatments requires a prescribing decision; using different mechanisms does not make a combination automatically safe.
Read: Sildenafil prescribing information; Tadalafil prescribing information; Vyleesi prescribing information.
Questions
What happens if I am not approved?
Your clinician explains the decision and, where useful, recommends a next step. If they determine you are not a candidate for any available treatment, any consultation fee paid is refunded within 7–10 business days. If you are approved and a prescription is issued, the consultation fee is non-refundable even if you do not proceed with a subscription.
Is compounded PT-141 the same as Vyleesi?
No. Vyleesi is an FDA-approved bremelanotide product for a specific indication. The injection offered here is compounded and is not FDA-approved. Its finished formulation has not undergone the same FDA premarket review.
Do I need to choose a medication before the Assessment?
You can arrive with a treatment in mind or a concern you want evaluated. Describe what has changed and share your medical history. The prescribing decision follows that review.
Sources
- Sildenafil prescribing information
DailyMed. Erectile dysfunction indication, mechanism and safety information.
- Tadalafil prescribing information
DailyMed. Erectile dysfunction indication, schedules and safety information.
- Kingsberg et al. Two randomized phase 3 bremelanotide trials
Obstetrics & Gynecology, 2019. DOI: 10.1097/AOG.0000000000003500.
- Rosen et al. Subcutaneous PT-141 in healthy men and men with ED
International Journal of Impotence Research, 2004. Early safety and pharmacodynamic research.
- Vyleesi prescribing information
DailyMed. Indication, contraindications, adverse reactions and interactions.
- FDA: Compounding questions and answers
The distinction between compounded medications and FDA-approved drug products.
